December 3, 2012 (MassDevice staff)
Namal Nawana, president of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes Spine, resigned from his role as worldwide president on November 27. He is pursuing opportunities outside of Johnson & Johnson, according to company communications director Debbie Williams.
Nawana became the president of DePuy Spine in March last year, having joined Johnson & Johnson Orthopedics as a technical support manager in the U.K. in 1997 and worked in engineering, marketing, sales and general management positions in Canada, Australia, and New Zealand.
Current worldwide marketing vice president Max Reinhardt will succeed Nawana to be the new president, Orthopedics This Week reported.
Reinhardt joined Johnson & Johnson at DePuy Spine in 2002 as director of sales & marketing in the U.K. and relocated to the U.S. as VP of U.S. sales for DePuy Spine in 2006. He was promoted to worldwide marketing VP in 2011.The executive shuffle comes amid tough times for the spinal products business. Global sales for the division were down 3% on an operational basis and U.S. sales were down approximately 6% during the last quarter, according to Orthopedics This Week.J&J in June paid $19.7 billion for the Swiss orthopedics giant to form the DePuy Synthes Cos. of Johnson & Johnson.
Nawana became the president of DePuy Spine in March last year, having joined Johnson & Johnson Orthopedics as a technical support manager in the U.K. in 1997 and worked in engineering, marketing, sales and general management positions in Canada, Australia, and New Zealand.
Current worldwide marketing vice president Max Reinhardt will succeed Nawana to be the new president, Orthopedics This Week reported.
Reinhardt joined Johnson & Johnson at DePuy Spine in 2002 as director of sales & marketing in the U.K. and relocated to the U.S. as VP of U.S. sales for DePuy Spine in 2006. He was promoted to worldwide marketing VP in 2011.The executive shuffle comes amid tough times for the spinal products business. Global sales for the division were down 3% on an operational basis and U.S. sales were down approximately 6% during the last quarter, according to Orthopedics This Week.J&J in June paid $19.7 billion for the Swiss orthopedics giant to form the DePuy Synthes Cos. of Johnson & Johnson.
(Visited 27 times, 7 visits today)